Xilio Therapeutics, Inc.XLOEarnings & Financial Report
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
XLO Q4 FY2025 Key Financial Metrics
Revenue
$13.7M
Gross Profit
N/A
Operating Profit
$-11.8M
Net Profit
$10.4M
Gross Margin
N/A
Operating Margin
-86.5%
Net Margin
75.7%
YoY Growth
N/A
EPS
$-3.74
Xilio Therapeutics, Inc. Q4 FY2025 Financial Summary
Xilio Therapeutics, Inc. reported revenue of $13.7M for Q4 FY2025, with a net profit of $10.4M (up 179.1% YoY) (75.7% margin).
Key Financial Metrics
| Total Revenue | $13.7M |
|---|---|
| Net Profit | $10.4M |
| Gross Margin | N/A |
| Operating Margin | -86.5% |
| Report Period | Q4 FY2025 |
Xilio Therapeutics, Inc. Annual Revenue by Year
Xilio Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $43.8M).
Xilio Therapeutics, Inc. Quarterly Revenue & Net Profit History
Xilio Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.7M | — | $10.4M | 75.7% |
| Q3 FY2025 | $19.1M | +742.5% | $-16.3M | -85.4% |
| Q2 FY2025 | $8.1M | +243.0% | $-15.8M | -196.0% |
| Q1 FY2025 | $2.9M | — | $-13.3M | -452.7% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $2.9M | $8.1M | $19.1M | $13.7M |
| YoY Growth | N/A | 243.0% | 742.5% | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $103.7M | $133.8M | $133.7M | $154.7M |
| Liabilities | $93.0M | $126.7M | $141.8M | $119.4M |
| Equity | $10.7M | $7.1M | $-8.1M | $35.3M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $29.0M | $-14.5M | $-17.5M | $-2.0M |